Vital Signs - Are Biosimilars On the U.S. Horizon?


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on June 23, 2008, provides an strategic overview of the issues surrounding generic biotechnology drugs and their approval pathway in the U.S. Additionally, a company spotlight is provided for InNexus Biotechnology, a biotechnology drug development company focused on next-generation monoclonal antibodies. Reimbursement and regulatory news from the FDA is also provided for the week of June 9, 2008.

Table of Contents

Vital Signs - Are Biosimilars On the U.S. Horizon?Vital Signs - 23 June 2008This week's issue:

Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.